Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.

Paulson DM, Kennedy DT, Donovick RA, Carpenter RL, Cherubini M, Techner L, Du W, Ma Y, Schmidt WK, Wallin B, Jackson D.

J Pain. 2005 Mar;6(3):184-92.

PMID:
15772912
2.

Alvimopan.

Curran MP, Robins GW, Scott LJ, Perry CM.

Drugs. 2008;68(14):2011-9. Review. Erratum in: Drugs. 2008;68(16):2324. Robyns, Gayle W [corrected to Robins, Gayle W].

PMID:
18778122
3.

Alvimopan.

Neary P, Delaney CP.

Expert Opin Investig Drugs. 2005 Apr;14(4):479-88. Review.

PMID:
15882122
4.

Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.

Schmidt WK.

Am J Surg. 2001 Nov;182(5A Suppl):27S-38S. Review.

PMID:
11755894
6.

Mu-opioid antagonists for opioid-induced bowel dysfunction.

McNicol ED, Boyce D, Schumann R, Carr DB.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006332. doi: 10.1002/14651858.CD006332.pub2. Review.

PMID:
18425947
7.

Alvimopan: a peripherally acting mu-opioid receptor antagonist.

Leslie JB.

Drugs Today (Barc). 2007 Sep;43(9):611-25. Review.

PMID:
17940638
8.

Novel opioid antagonists for opioid-induced bowel dysfunction.

Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF.

Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56. doi: 10.1517/13543784.2011.592830. Epub 2011 Jun 12. Review.

PMID:
21663526
9.

Opioid-induced bowel dysfunction: pathophysiology and potential new therapies.

Kurz A, Sessler DI.

Drugs. 2003;63(7):649-71. Review.

PMID:
12656645
10.

[News from the cochrane library: mu opioid antagonists for opioid-induced bowel dysfunction].

Meerpohl JJ, Timmer A.

Z Gastroenterol. 2008 Sep;46(9):917-21. doi: 10.1055/s-2008-1027720. Epub 2008 Sep 22. Review. German.

PMID:
18810678
11.

Incidence, prevalence, and management of opioid bowel dysfunction.

Pappagallo M.

Am J Surg. 2001 Nov;182(5A Suppl):11S-18S. Review.

PMID:
11755892
12.

Management of opioid-induced bowel dysfunction in cancer patients.

Tamayo AC, Diaz-Zuluaga PA.

Support Care Cancer. 2004 Sep;12(9):613-8. Review.

PMID:
15221581
13.

A review of the potential role of methylnaltrexone in opioid bowel dysfunction.

Foss JF.

Am J Surg. 2001 Nov;182(5A Suppl):19S-26S. Review.

PMID:
11755893
14.

Alvimopan for postoperative ileus.

Bream-Rouwenhorst HR, Cantrell MA.

Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77. doi: 10.2146/ajhp080445. Review.

PMID:
19574601
15.

Alvimopan, a selective peripherally acting mu-opioid antagonist.

Camilleri M.

Neurogastroenterol Motil. 2005 Apr;17(2):157-65. Review.

16.

Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden.

Panchal SJ, Müller-Schwefe P, Wurzelmann JI.

Int J Clin Pract. 2007 Jul;61(7):1181-7. Epub 2007 May 4. Review.

17.

Fentanyl buccal tablet.

Messina J, Darwish M, Fine PG.

Drugs Today (Barc). 2008 Jan;44(1):41-54. doi: 10.1358/dot.2008.44.1.1178469. Review.

PMID:
18301803
18.

Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone.

Rauck RL.

Drugs. 2013 Aug;73(12):1297-306. doi: 10.1007/s40265-013-0084-5. Review.

PMID:
23881667
19.

Opioid-induced constipation: challenges and therapeutic opportunities.

Camilleri M.

Am J Gastroenterol. 2011 May;106(5):835-42; quiz 843. doi: 10.1038/ajg.2011.30. Epub 2011 Feb 22. Review.

PMID:
21343919
20.

Treatment of opioid-induced gut dysfunction.

Holzer P.

Expert Opin Investig Drugs. 2007 Feb;16(2):181-94. Review.

PMID:
17243938
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk